Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities

Biochemistry

Volumn 44, Issue 5, 2005, Pages 1595-1606

  Shaw Reid, Cathryn A ^a,b   Feuston, Bradley ^a   Munshi, Vandna ^a   Getty, Krista ^a   Krueger, Julie ^a   Hazuda, Daria J ^a   Parniak, Michael A ^c   Miller, Michael D ^a   Lewis, Dale ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CRYSTAL STRUCTURE; ENZYME KINETICS; ENZYMES; GELS; ORGANIC ACIDS; RNA;

DIKETO ACID (DKA); NONNUCLEOSIDE RT INHIBITORS (NNRTIS); PYROPHOSPHATE; REVERSE TRANSCRIPTION (RT);

DNA;

3' AZIDO 3' DEOXYTHYMIDINE TRIPHOSPHATE; DNA POLYMERASE; FOSCARNET; OXOACID; PROTEIN P66; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE DERIVATIVE;

ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; DNA RNA HYBRIDIZATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS GENOME;

ANTI-HIV AGENTS; BINDING SITES; BUTYRIC ACIDS; CATALYSIS; DNA-DIRECTED DNA POLYMERASE; DRUG COMBINATIONS; DRUG SYNERGISM; FOSCARNET; HIV-1 REVERSE TRANSCRIPTASE; HYDROLYSIS; KINETICS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS; THIOPHENES; THYMINE NUCLEOTIDES; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 13444257639     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0486740     Document Type: Article

References (34)

1. Farthing, C. F., Dalgleish, A. G., Clark, A., McClure, M., Chanas, A., and Gazzard, B. G. (1987) Phosphonoformate (foscarnet): A pilot study in AIDS and AIDS related complex, AIDS 1, 21-25.
2. Mellors, J. W., Bazmi, H. Z., Schinazi, R. F., Roy, B. M., Hsiou, Y., Arnold, E., Weir, J., and Mayers, D. L. (1995) Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates, Antimicrob. Agents Chemother. 39, 1087-1092.
3. Palaniappan, C., Wisniewski, M., Jacques, P. S., Le Grice, S. F., Fay, P. J., and Bambara, R. A. (1997) Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNasè H function, J. Biol. Chem. 272, 11157-11164.
4. Rausch, J. W., Lener, D., Miller, J. T., Julias, J. G., Hughes, S. H., and Le Grice, S. F. (2002) Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity, Biochemistry 41, 4856-4865.
5. Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2002) Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo, Proc. Natl. Acad. Sci. U.S.A. 99, 9515-9520.
6. Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Alvord, W. G., Arnold, E., and Hughes, S. H. (2003) Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity, J. Virol. 77, 8548-8554.
7. Palaniappan, C., Fay, P. J., and Bambara, R. A. (1995) Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase, J. Biol. Chem. 270, 4861-4869.
8. Gopalakrishnan, V., and Benkovic, S. (1994) Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase, J. Biol. Chem. 269, 4110-4115.
9. Archer, R. H., Dykes, C., Gerondelis, P., Lloyd, A., Fay, P., Reichman, R. C., Bambara, R. A., and Demeter, L. M. (2000) Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture, J. Virol. 74, 8390-8401.
10. Archer, R. H., Wisniewski, M., Bambara, R. A., and Demeter, L. M. (2001) The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages, Biochemistry 40, 4087-4095.
11. Gerondelis, P., Archer, R. H., Palaniappan, C., Reichman, R. C., Fay, P. J., Bambara, R. A., and Demeter, L. M. (1999) The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities, J. Virol. 73, 5803-5813.
12. Parniak, M. A., Min, K. L., Budihas, S. R., Le Grice, S. F., and Beutler, J. A. (2003) A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity, Anal. Biochem. 322, 33-39.
13. Shaw-Reid, C. A., Munshi, V., Graham, P., Wolfe, A., Witmer, M., Danzeisen, R., Olsen, D. B., Carroll, S. S., Embrey, M., Wai, J. S., Miller, M. D., Cole, J. L., and Hazuda, D. J. (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278, 2777-2780.
14. Young, S. D., Britcher, S. F., Payne, L. S., Tran, L. O., and Lumma, W. C. (1995) U.S. Patent 5,519,021.
15. Gabbara, S., Davis, W. R., Hupe, L., Hupe, D., and Peliska, J. A. (1999) Inhibitors of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase, Biochemistry 38, 13070-13076.
16. Segel, I. H. (1975) pp 474-488, John Wiley and Sons, Inc., New York.
17. Chou, T. C., and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul. 22, 27-55.
18. Davis, W. R., Tomsho, J., Nikam, S., Cook, E. M., Somand, D., and Peliska, J. A. (2000) Inhibition of HIV-1 reverse transcriptase-catalyzed DNA strand transfer reactions by 4-chlorophenylhydrazone of mesoxalic acid, Biochemistry 39, 14279-14291.
19. Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., Carroll, S. S., et al. (1995) L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother. 39, 2602-2605.
20. King, R. W., Klabe, R. M., Reid, C. D., and Erickson-Viitanen, S. K. (2002) Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors, Antimicrob. Agents Chemother. 46, 1640-1646.
21. Carroll, S. S., Stahlhut, M., Geib, J., and Olsen, D. B. (1994) Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. Differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs, J. Biol. Chem. 269, 32351-32357.
22. Kong, X. B., Zhu, Q. Y., Ruprecht, R. M., Watanabe, K. A., Zeidler, J. M., Gold, J. W., Polsky, B., Armstrong, D., and Chou, T. C. (1991) Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3′-azido-3′-deoxythymidine, phosphonoformate, and 2′,3′-dideoxythymidine, Antimicrob. Agents Chemother. 35, 2003-2011.
23. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Jr., Hughes, S. H., and Arnold, E. (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms, Structure 4, 853-860.
24. Sarafianos, S. G., Das, K., Tantillo, C., Clark, A. D., Jr., Ding, J., Whitcomb, J. M., Boyer, P. L., Hughes, S. H., and Arnold, E. (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA, EMBO J. 20, 1449-1461.
25. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank, Nucleic Acids Res. 28, 235-242.
26. Temiz, N. A., and Bahar, I. (2002) Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase, Proteins 49, 61-70.
27. Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P. A., Hughes, S. H., and Arnold, E. (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors, Nat. Struct. Biol. 2, 407-415.
28. Amadei, A., Linssen, A. B., and Berendsen, H. J. (1993) Essential dynamics of proteins, Proteins 17, 412-425.
29. Chau, P. L., van Aalten, D. M., Bywater, R. P., and Findlay, J. B. (1999) Functional concerted motions in the bovine serum retinol-binding protein, J. Comput.-Aided Mol. Des. 13, 11-20.
30. Shen, L., Shen, J., Luo, X., Cheng, F., Xu, Y., Chen, K., Arnold, E., Ding, J., and Jiang, H. (2003) Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT, Biophys. J. 84, 3547-3563.
31. Madrid, M., Lukin, J. A., Madura, J. D., Ding, J., and Arnold, E. (2001) Molecular dynamics of HIV-1 reverse transcriptase indicates increased flexibility upon DNA binding, Proteins 45, 176-182.
32. Telesnitsky, A., and Goff, S. P. (1993) Two defective forms of reverse transcriptase can complement to restore retroviral infectivity, EMBO J. 12, 4433-4438.
33. Julias, J. G., Ferris, A. L., Boyer, P. L., and Hughes, S. H. (2001) Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase, J. Virol. 75, 6537-6546.
34. Hwang, C. K., Svarovskaia, E. S., and Pathak, V. K. (2001) Dynamic copy choice: Steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching, Proc. Natl. Acad. Sci. U.S.A. 98, 12209-12214.